ATNM Relative Valuation
ATNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATNM is overvalued; if below, it's undervalued.
Historical Valuation
Actinium Pharmaceuticals Inc (ATNM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.91. The fair price of Actinium Pharmaceuticals Inc (ATNM) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.43
Fair
-1.61
PE
1Y
3Y
5Y
0.25
EV/EBITDA
Actinium Pharmaceuticals Inc. (ATNM) has a current EV/EBITDA of 0.25. The 5-year average EV/EBITDA is -1.68. The thresholds are as follows: Strongly Undervalued below -4.86, Undervalued between -4.86 and -3.27, Fairly Valued between -0.09 and -3.27, Overvalued between -0.09 and 1.50, and Strongly Overvalued above 1.50. The current Forward EV/EBITDA of 0.25 falls within the Overvalued range.
0.31
EV/EBIT
Actinium Pharmaceuticals Inc. (ATNM) has a current EV/EBIT of 0.31. The 5-year average EV/EBIT is -1.61. The thresholds are as follows: Strongly Undervalued below -6.18, Undervalued between -6.18 and -3.90, Fairly Valued between 0.68 and -3.90, Overvalued between 0.68 and 2.96, and Strongly Overvalued above 2.96. The current Forward EV/EBIT of 0.31 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Actinium Pharmaceuticals Inc. (ATNM) has a current PS of 0.00. The 5-year average PS is 220.75. The thresholds are as follows: Strongly Undervalued below -655.69, Undervalued between -655.69 and -217.47, Fairly Valued between 658.98 and -217.47, Overvalued between 658.98 and 1097.20, and Strongly Overvalued above 1097.20. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.58
P/OCF
Actinium Pharmaceuticals Inc. (ATNM) has a current P/OCF of -1.58. The 5-year average P/OCF is -2.11. The thresholds are as follows: Strongly Undervalued below -15.53, Undervalued between -15.53 and -8.82, Fairly Valued between 4.60 and -8.82, Overvalued between 4.60 and 11.31, and Strongly Overvalued above 11.31. The current Forward P/OCF of -1.58 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Actinium Pharmaceuticals Inc. (ATNM) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.63. The thresholds are as follows: Strongly Undervalued below -37.23, Undervalued between -37.23 and -20.43, Fairly Valued between 13.17 and -20.43, Overvalued between 13.17 and 29.97, and Strongly Overvalued above 29.97. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Actinium Pharmaceuticals Inc (ATNM) has a current Price-to-Book (P/B) ratio of 3.10. Compared to its 3-year average P/B ratio of 3.14 , the current P/B ratio is approximately -1.16% higher. Relative to its 5-year average P/B ratio of 2.75, the current P/B ratio is about 12.55% higher. Actinium Pharmaceuticals Inc (ATNM) has a Forward Free Cash Flow (FCF) yield of approximately -58.59%. Compared to its 3-year average FCF yield of -41.02%, the current FCF yield is approximately 42.83% lower. Relative to its 5-year average FCF yield of -28.58% , the current FCF yield is about 104.99% lower.
3.10
P/B
Median3y
3.14
Median5y
2.75
-58.59
FCF Yield
Median3y
-41.02
Median5y
-28.58
Competitors Valuation Multiple
The average P/S ratio for ATNM's competitors is 33.44, providing a benchmark for relative valuation. Actinium Pharmaceuticals Inc Corp (ATNM) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ATNM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ATNM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Actinium Pharmaceuticals Inc (ATNM) currently overvalued or undervalued?
Actinium Pharmaceuticals Inc (ATNM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.91. The fair price of Actinium Pharmaceuticals Inc (ATNM) is between to according to relative valuation methord.
What is Actinium Pharmaceuticals Inc (ATNM) fair value?
ATNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Actinium Pharmaceuticals Inc (ATNM) is between to according to relative valuation methord.
How does ATNM's valuation metrics compare to the industry average?
The average P/S ratio for ATNM's competitors is 33.44, providing a benchmark for relative valuation. Actinium Pharmaceuticals Inc Corp (ATNM) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Actinium Pharmaceuticals Inc (ATNM) as of Jan 08 2026?
As of Jan 08 2026, Actinium Pharmaceuticals Inc (ATNM) has a P/B ratio of 3.10. This indicates that the market values ATNM at 3.10 times its book value.
What is the current FCF Yield for Actinium Pharmaceuticals Inc (ATNM) as of Jan 08 2026?
As of Jan 08 2026, Actinium Pharmaceuticals Inc (ATNM) has a FCF Yield of -58.59%. This means that for every dollar of Actinium Pharmaceuticals Inc’s market capitalization, the company generates -58.59 cents in free cash flow.
What is the current Forward P/E ratio for Actinium Pharmaceuticals Inc (ATNM) as of Jan 08 2026?
As of Jan 08 2026, Actinium Pharmaceuticals Inc (ATNM) has a Forward P/E ratio of -1.61. This means the market is willing to pay $-1.61 for every dollar of Actinium Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Actinium Pharmaceuticals Inc (ATNM) as of Jan 08 2026?
As of Jan 08 2026, Actinium Pharmaceuticals Inc (ATNM) has a Forward P/S ratio of 0.00. This means the market is valuing ATNM at $0.00 for every dollar of expected revenue over the next 12 months.